Chemours Cuts FY22 Adj. EBITDA Outlook; Stock Down

The Chemours Company (CC), a chemical firm, said on Wednesday that it has revised down its Adjusted EBITDA guidance for the fiscal 2022, after its Titanium Technologies segment experienced a continued fall in demand throughout the third quarter.

For the full-year, the Delaware-headquartered firm now expects its adjusted EBITDA to be in the range of $1.400 billion and $1.450 billion, or at its midpoint around 7 percent below the midpoint of the prior guidance range, but about 9 percent above the prior year.

On July 28, for the fiscal 2022, the firm had projected its Adjusted EBITDA to be at the high end of the previously updated outlook range of $1.475 billion to $1.575 billion.

For the fiscal 2021, Chemours had reported adjusted EBITDA of $1.313 billion.

Mark Newman, CEO of Chemours, said: "In our TT segment, we have experienced a continued decline in our demand outlook throughout the third quarter, most notably in Europe and Asia. Lower demand, coupled with continued high input costs, have impacted our projected results for the full year. In response, we will be extending a scheduled outage on one of our TT production lines, in addition to other cost actions…"

CC was trading down by 6.57 percent at $28.71 per share in pre-market on the New York Stock Exchange.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Japanese auto major Toyota Motor Corp. has retained its title as the world's top selling automaker in fiscal 2022 for the third straight year, by selling around 10.5 million vehicles. The global sales were nearly flat with last year amid solid demand centered around Asia, while global production grew with increased capacity and production optimization in North America and Asia. Dutch consumer electronics giant Philips Electronics NV reported Monday a loss in its fourth quarter, compared to prior year's profit, even as sales increased. The company further declared a dividend, and said its order book remains strong. Going ahead, the company projects comparable sales growth in fiscal 2023, 2025, and beyond. Sovos Brands Intermediate, Inc. is recalling a limited number of 16-ounce jars of Rao's Made for Home Slow Simmered Soup, Chicken & Gnocchi citing undeclared egg, an allergen, the U.S. Food and Drug Administration said. The affected soup is labeled as Chicken & Gnocchi, but will contain vegetable minestrone, which is dark red.
Follow RTT